SCHEMBL6462990

SCHEMBL6462990

Cc1cc(N[C@H]2CC[C@@H](CNC(=O)Nc3cccc(Cl)c3Cl)CC2)nc2ccccc12

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
KDM4E B2RXH2 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
NPY5R Q15761 4/20 0.43
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.40
RAB9A P51151 1/20 0.40
NUDT1 P36639 1/20 0.40
KDR P35968 1/20 0.40
ACACB O00763 1/20 0.40
ACACA Q13085 1/20 0.40
MCHR1 Q99705 1/20 0.39
MAPT P10636 1/20 0.39
MAPK14 Q16539 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6462989 1.00 LMNA (0.49) LMNAKDM4ESMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL6458233 0.99 LMNA (0.48) LMNAKDM4ESMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL6458227 0.99 LMNA (0.48) LMNAKDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL6456897 0.89 MEN1 (0.42) LMNAKDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL6456892 0.89 MEN1 (0.42) LMNAKDM4ESMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL6459011 0.88 MEN1 (0.41) LMNAKDM4ESMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL6459006 0.88 MEN1 (0.41) LMNAKDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL6462132 0.88 SMN1; SMN2 (0.54) LMNAKDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL6462137 0.88 SMN1; SMN2 (0.54) LMNAKDM4ESMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL6455558 0.87 SMN1; SMN2 (0.53) LMNAKDM4ESMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US claimed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO claimed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP claimed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 LMNA 3391/4885KDM4E 1190/4885SMN1; SMN2 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.